Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575002 | 0.94 | ADRA1B (0.49) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| SCHEMBL3943706 | 0.94 | L3MBTL1 (0.47) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| SCHEMBL17219124 | 0.92 | ADRA1B (0.48) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| SCHEMBL2814030 | 0.88 | L3MBTL1 (0.46) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| SCHEMBL507643 | 0.87 | — | — | |
| SCHEMBL5424673 | 0.87 | PIK3CD (0.54) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| SCHEMBL10975726 | 0.86 | L3MBTL1 (0.49) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| SCHEMBL10974389 | 0.86 | L3MBTL1 (0.45) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5475006 | 0.85 | PIK3CD (0.48) | PIK3CDADRA1BADRA1AKMT2AMEN1 | |
| SCHEMBL19514132 | 0.85 | PIK3CD (0.52) | PIK3CDADRA1BADRA1AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0911330-B1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | claimed |
| US-6084097-A | BY CONDENSING A PYRIDYL PIPERAZINE OR A SUBSTITUTED PHENYL PIPERAZINE WITH 1-CHLORO-3-(2-OXOPYRROLIDIN-1-YL)PROPANE OR 1-CHLORO-3-(2-OXOPIPERIDIN-1-YL)PROPANE IN THE PRESENCE OF A BASE, A CATALYST AND ORGANIC SOLVENT; ANTIHYPERTENSIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2000-07-04 | — | — | US | claimed |
| EP-0911330-A1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific & Industrial Research (IN) | 1999-04-28 | — | — | EP | claimed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| WO-2004054946-A1 | HYDROFORMYLATION PROCESS FOR THE CONVERSION OF AN ETHYLENICALLY UNSATURATED COMPOUND TO AN ALCOHOL | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2004-07-01 | — | — | WO | disclosed |
| EP-1392298-A2 | FUSED HETEROCYCLIC COMPOUNDS | Tularik Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030176694-A1 | Fused heterocyclic compounds | AMGEN INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030023085-A1 | Fused heterocyclic compounds | TULARIK INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002089729-A2 | FUSED HETEROCYCLIC COMPOUNDS | TULARIK INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-6150367-A | 1-(4-ARYLPIPERAZIN-1-YL)-3-(2-OXOPYRROLIDIN-1-YL )PROPANE OR 1-(4-ARYLPIPERAZIN-1-YL)-3-(2-OXOPIPERIDIN-1-YL )PROPANE CAN BE USED AS THERAPEUTIC AGENTS FOR HYPERTENSION, ISCHEMIA, AND OTHER CARDIOVASCULAR DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2000-11-21 | — | — | US | disclosed |
| US-6084097-A | BY CONDENSING A PYRIDYL PIPERAZINE OR A SUBSTITUTED PHENYL PIPERAZINE WITH 1-CHLORO-3-(2-OXOPYRROLIDIN-1-YL)PROPANE OR 1-CHLORO-3-(2-OXOPIPERIDIN-1-YL)PROPANE IN THE PRESENCE OF A BASE, A CATALYST AND ORGANIC SOLVENT; ANTIHYPERTENSIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2000-07-04 | — | — | US | disclosed |
| EP-0913397-A1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific and Industrial Research (IN) | 1999-05-06 | — | — | EP | disclosed |
| EP-0911330-A1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific & Industrial Research (IN) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CD 146/4885ADRA1B 4067/4885ADRA1A 4460/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | PIK3CD 535/4885ADRA1B 4223/4885ADRA1A 4180/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | PIK3CD 180/4885ADRA1B 3981/4885ADRA1A 4458/4885 |
| US-20030023085-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | PIK3CD 1004/4885ADRA1B 389/4885ADRA1A 357/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | PIK3CD 215/4885ADRA1B 4573/4885ADRA1A 4631/4885 |
| US-20030176694-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | PIK3CD 1004/4885ADRA1B 389/4885ADRA1A 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.